Congress is negotiating sweeping legislation that impacts life sciences. Colorado BioScience Association (CBSA) remains active on these important legislative proposals, which include supporting the reauthorizations of PDUFA + MDUFA, urging reauthorization of SBIR + STTR programs, monitoring and advocating for the VALID Act, and engaging on the recent reconciliation package that includes updated drug pricing text.
Advocating for VALID ACT within Reauthorization of User Fee Programs
CBSA and several state life sciences associations, patient groups and other stakeholders signed onto a support letter led by AdvaMed to Chairman Pallone, Chair Murray, and Ranking Members Rogers and Burr. As negotiations for the user fee reauthorizations are ongoing, this letter reinforces CBSA’s and the industry’s commitment to ensuring patient access to accurate and reliable in vitro diagnostics.
CBSA has previously signed onto support letters for VALID Act. As Congress works on reconciling differences between the user…
Click here to view original post